🏛️ Verified NIH Record • Updated 2026-08-12
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (NCT06087458)
Phase 1/2a Study of VOY-101 in Subjects With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Perceive Biotherapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Who can join: Review the eligibility criteria below.
Location: Retina Macula Institute of AZ — Scottsdale, Arizona
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Retina Macula Institute of AZ — Scottsdale, Arizona
- Retina Consultants San Diego — Poway, California
- Retinal Consultants Medical Group — Sacramento, California
- Ophthalmic Consultants of Boston — Boston, Massachusetts
- The Retina Institute — St Louis, Missouri
- Mid Atlantic Retina — Cherry Hill, New Jersey
- Retina Northwest — Portland, Oregon
- Black Hills Regional Eye Institute — Rapid City, South Dakota
- Austin Research Center for Retina — Austin, Texas
- Star Retina — Fort Worth, Texas
- Retina Center of Texas — Southlake, Texas
- University of Utah John A. Moran Eye Center — Salt Lake City, Utah
- Sydney Retina Clinic and Day Surgery — Sydney, New South Wales
- Cerulea Clinical Trials — East Melbourne, Victoria
- Rambam Medical Center — Haifa,
- Tel-Aviv Sourasky Medical Center, Ophthalmology Division — Tel Aviv,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.